Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250679 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 443
- Enrollment target
- 20
- Study locations
NCT00250679 is a Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema that has completed, run by Sumitomo Pharma America. The registered enrollment target is 443 participants, below the 1,749-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00250679, a Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 443 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Arformoterol tartrate inhalation solution
- DRUG Arformoterol 25 ųg BID
- DRUG Formoterol 12 ųg BID
Study Locations (20)
California
- - Carmichael
- - Fullerton
- - Long Beach
- - Paramount
- - Rancho Mirage
- - San Diego
- - Walnut Creek
Florida
- - Bay Pines
- - Brandon
- - Gainesville
- - Panama City
- - Tampa
Alabama
- - Birmingham
- - Jasper
- - Mobile
Georgia
- - Atlanta
- - Marietta
Arkansas
- - Little Rock
Colorado
- - Denver
Connecticut
- - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 443 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00250679
The ClinicalTrials.gov registry entry for NCT00250679 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 443 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,749-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (75% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00250679 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00250679 about?
NCT00250679 is a clinical study titled "Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease". To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00250679?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 443 participants. The study started on 2005-10. Estimated completion is 2007-10.
What conditions does trial NCT00250679 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, Emphysema, Bronchitis.
What interventions are being tested in trial NCT00250679?
The interventions under investigation include: Placebo (DRUG), Arformoterol tartrate inhalation solution (DRUG), Arformoterol 25 ųg BID (DRUG), Formoterol 12 ųg BID (DRUG).
Who is sponsoring clinical trial NCT00250679?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00250679 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.